Amarin (AMRN) Competitors $15.78 -0.32 (-1.99%) Closing price 07/15/2025Extended Trading$15.88 +0.10 (+0.60%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. MESO, EWTX, TVTX, CVAC, PAHC, ABCL, CALT, HROW, WVE, and AMPHShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Mesoblast (MESO), Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), CureVac (CVAC), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Calliditas Therapeutics AB (publ) (CALT), Harrow (HROW), WAVE Life Sciences (WVE), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Its Competitors Mesoblast Edgewise Therapeutics Travere Therapeutics CureVac Phibro Animal Health AbCellera Biologics Calliditas Therapeutics AB (publ) Harrow WAVE Life Sciences Amphastar Pharmaceuticals Amarin (NASDAQ:AMRN) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Do analysts rate AMRN or MESO? Amarin presently has a consensus target price of $12.00, indicating a potential downside of 23.95%. Mesoblast has a consensus target price of $18.00, indicating a potential upside of 64.23%. Given Mesoblast's stronger consensus rating and higher probable upside, analysts clearly believe Mesoblast is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, AMRN or MESO? Amarin has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500. Which has stronger earnings & valuation, AMRN or MESO? Amarin has higher revenue and earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M1.43-$82.18M-$3.64-4.34Mesoblast$5.90M237.37-$87.96MN/AN/A Is AMRN or MESO more profitable? Mesoblast has a net margin of 0.00% compared to Amarin's net margin of -41.07%. Mesoblast's return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-41.07% -17.21% -12.16% Mesoblast N/A N/A N/A Do institutionals & insiders hold more shares of AMRN or MESO? 22.3% of Amarin shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 2.0% of Amarin shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer AMRN or MESO? In the previous week, Amarin and Amarin both had 2 articles in the media. Amarin's average media sentiment score of 1.00 beat Mesoblast's score of 0.66 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMesoblast beats Amarin on 10 of the 14 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$326.80M$2.90B$5.53B$9.30BDividend YieldN/A2.43%4.59%4.02%P/E Ratio-4.3420.2228.5619.60Price / Sales1.43186.60360.9274.26Price / CashN/A41.0524.7327.56Price / Book0.677.618.155.56Net Income-$82.18M-$55.11M$3.24B$257.73M7 Day Performance-6.24%7.56%2.01%0.97%1 Month Performance19.09%11.47%8.27%10.70%1 Year Performance5.06%0.89%28.39%15.67% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.2929 of 5 stars$15.78-2.0%$12.00-24.0%+3.1%$326.80M$228.61M-4.34360Positive NewsMESOMesoblast2.3311 of 5 stars$10.53-1.4%$18.00+70.9%+38.8%$1.35B$5.90M0.0080EWTXEdgewise Therapeutics1.4794 of 5 stars$12.61-3.2%$40.00+217.2%-37.9%$1.33BN/A-8.1460TVTXTravere Therapeutics3.8307 of 5 stars$14.60-2.7%$32.14+120.2%+72.6%$1.30B$273.53M-5.20460CVACCureVac4.738 of 5 stars$5.41-0.7%$6.83+26.3%+67.5%$1.21B$523.70M5.88880Positive NewsPAHCPhibro Animal Health4.0203 of 5 stars$29.90+6.8%$24.40-18.4%+80.4%$1.21B$1.02B38.331,940High Trading VolumeABCLAbCellera Biologics2.1223 of 5 stars$4.03+6.1%$7.50+86.1%+35.9%$1.20B$28.83M-7.20500News CoverageAnalyst ForecastHigh Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180HROWHarrow2.2198 of 5 stars$31.36-1.2%$61.40+95.8%+50.9%$1.15B$199.61M-56.00180News CoverageAnalyst RevisionWVEWAVE Life Sciences4.4262 of 5 stars$7.06+1.6%$20.50+190.4%+39.5%$1.10B$108.30M-8.40240AMPHAmphastar Pharmaceuticals4.3162 of 5 stars$22.86-1.5%$32.33+41.4%-43.3%$1.08B$731.97M8.282,028News Coverage Related Companies and Tools Related Companies Mesoblast Alternatives Edgewise Therapeutics Alternatives Travere Therapeutics Alternatives CureVac Alternatives Phibro Animal Health Alternatives AbCellera Biologics Alternatives Calliditas Therapeutics AB (publ) Alternatives Harrow Alternatives WAVE Life Sciences Alternatives Amphastar Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRN Stock Alerts